-
PROVIDERS
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
LIFE SCIENCES
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
Content
-
ArticlesQ&A: AI algorithms in cardiology: From research to clinical practice
In a recent webinar hosted by Tempus, experts gathered to discuss the integration of AI algorithms into cardiology, focusing on the journey from research to practical application in patient care. -
Case StudiesNavigating complex cell therapy trials with Compass CRO
Learn how Compass provided CRO services for a biotech’s first-in-human, dose-escalation, and expansion basket trial targeting advanced solid tumors. -
ArticlesQ&A: Harnessing AI with multimodal data to transform drug development
Dr. Kate Sasser, PhD, Chief Scientific Officer at Tempus, discusses how Tempus layers ML and AI on multimodal data to drive insights and propel various stages of drug discovery and development. -
WebinarsPrecision pathways: Insights & strategies to navigate regulatory requirements for oncology diagnostics
Watch as we explore the evolving regulatory landscape of diagnostics in oncology. Gain insights into new regulatory requirements, submission pathways, and emerging trends. Learn from industry experts about strategic approaches to FDA requirements to help inform your diagnostic development and precision medicine pipelines. -
Case StudiesRevolutionizing drug screening with Tempus AI’s advanced imaging capabilities
Learn how Tempus AI's noninvasive imaging techniques allow for the continuous study of the same organoids across various assays, preserving their viability for longitudinal analysis and multiplexed testing. -
WebinarsShaping drug development with tumor organoids and RWD
Explore how Tempus addresses drug development challenges through its extensive 3D patient-derived organoid (PDO) biorepository and real-world data (RWD) platform. -
Case StudiesHarnessing AI and TIME to increase clinical trial enrollment
Cleveland Clinic studies the impact of AI to meaningfully streamline and increase trial access and enrollment. -
WebinarsAI algorithms in cardiology: Navigating the path from research to practice
Unlock the Future of Cardiology with AI. Join Tempus for an in-depth webinar exploring the transformative power of AI algorithms in cardiology research and clinical practice. -
Webinars
Enhancing psychiatric care with pharmacogenomics (PGx)
Tune in as clinicians discuss PGx, and its application in psychiatric medication management. Our expert speakers will guide you through patient case studies and real-world PGx reports, and highlight the role of pharmacogenomics to inform personalized treatment decisions in mental health. -
ArticlesQ&A: Advancing immunotherapy biomarker identification with Immune Profile Score (IPS)
Jason Blue-Smith, VP & GM of Algos at Tempus, discusses the challenges in immunotherapy biomarker identification and how Tempus’ Immune Profile Score (IPS) offers solutions to these problems. -
Webinars
Scientific breakthroughs across the cancer continuum: Research from the 2024 ASCO® Annual Meeting
Join experts as they discuss innovative approaches to patient management in cancer care. Learn about new data from the 2024 ASCO® Annual Meeting, including Tempus' new MRD and monitoring portfolio, major lung cancer trial discoveries, and advancements in outcomes for advanced breast cancer. -
ArticlesQ&A: The evolving role of antibody-drug conjugates in oncology
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. -
Webinars
Integrating Omics in R&D: A new era of biomedical research
Industry experts discuss the integration of diverse omics data, from next-generation sequencing (NGS) to proteomics, and explore its transformative impact on the research landscape. -
Webinars
Harnessing the power of AI: Optimizing workflows & enhancing testing across the cancer care continuum
Learn how AI is improving cancer care by making it more precise, tailored, and successful. Our newest tools, including One, Lens, Next, and Link, are making clinical and research work more efficient. Our move into MRD and monitoring uses these tools to better track patient progress and help healthcare and pharmaceutical partners monitor treatments. -
ArticlesTempus receives U.S. FDA 510(k) clearance for Tempus ECG-AF, an AI-based algorithm that identifies patients at increased risk of AFib
Tempus AI, Inc. (NASDAQ: TEM), a leader in AI and precision medicine, announced it has received 510(k) clearance from the FDA for its Tempus ECG-AF device. This AI-based algorithm helps identify patients who may be at increased risk of atrial fibrillation/flutter (AF), marking the first FDA clearance for an AF indication in the "cardiovascular machine learning-based notification software" category. -
Case StudiesRevolutionizing Cardiac Care: AI-driven detection and treatment of critical heart valve disease at Boulder Community Health
Discover how Tempus Next's AI-powered care pathway platform transformed patient outcomes by helping ensure timely, guideline-directed treatment for critical heart valve disease at Boulder Community Health -
VideosEmbracing AI in oncology: A fireside chat with industry leaders at AACR 2024
Industry leaders highlight the importance of multimodal data, AI-driven diagnostics, and the necessity of innovative approaches to meet the challenges of oncology treatment. -
WebinarsADCs in focus: The next generation of precision medicine in oncology
Join the conversation with experts as they discuss the progress of antibody-drug conjugates (ADCs) in cancer treatment. They'll cover issues with early ADCs, how they work with immune therapies, and future targets and methods. Tempus supports ADC improvement by providing detailed genetic analysis, anonymous patient data, and AI tools to help find new targets and make clinical trials better for personalized treatments. -
Case StudiesAdvancing transcriptional cancer therapies with Tempus’ comprehensive life science solutions
Kronos Bio, a trailblazer in the biopharmaceutical industry, is dedicated to the discovery and development of novel therapies that target transcriptional regulation in cancer.
